GO
Loading...

Medicine

More

  • Amgen, Johnson & Johnson & The FDA Tuesday, 11 Mar 2008 | 1:23 PM ET

    Shares of biotech giant Amgen fell as low as $43.14 (a new bottom) this morning after the briefing documents for Thursday's Food and Drug Administration Advisory Committee meeting were posted on the agency's website.

  • One Giant Leap for MannKind Monday, 10 Mar 2008 | 5:11 PM ET

    Billionaire Alfred Mann must not have liked watching stock in the company bearing his name fall to another new low today in the wake of Eli Lilly giving up on inhaled insulin.

  • Amgen And Genentech: A Big Biotech Double Play Monday, 10 Mar 2008 | 10:50 AM ET
    AMGEN

    This is a big week for the world's top-two biotechnology companies and their investors. Amgen goes before an FDA Advisory Committee Thursday about the side effects of its bread-and-butter franchise Aranesp.

  • First, Pfizer gave up on its inhaled insulin Exubera, then NovoNordisk threw in the towel and now it looks like Lilly is going to bow out. Alkermes, which is working on a palm-sized product called, "AIR Insulin," put out a press release today saying it expects its partner on the device, Lilly, to decide next week that it will exit the deal. ALKS shares hit a new low on the news.

  • Analyst: Pfizer Should Buy Amgen or Wyeth Friday, 7 Mar 2008 | 10:48 AM ET

    I thought I was finished with the post-Pfizer analyst meeting reaction with yesterday's post, but when an extraordinarily bearish 77-page research note from Credit Suisse big pharma analyst Catherine Arnold arrived in my inbox this morning, I had to do one more installment. She thinks Pfizer should buy Wyeth or Amgen...

  • Pfizer Analyst Day: The Analysts React Thursday, 6 Mar 2008 | 10:16 AM ET

    Pfizer held its analyst day yesterday and the stock closed at a new multi-year low. This morning the shares are under a little bit of pressure again as analyst reaction to the event pours in.

  • FDA Turns Over Dendreon Documents Wednesday, 5 Mar 2008 | 3:49 PM ET

    When I got back from the Pfizer analyst meeting in New York City this afternoon, I found a treasure trove of PDF documents in one of my inboxes from a couple of Dendreon/Provenge proponents from their Freedom of Information Act request to the Food and Drug Administration...

  • Pfizer CEO: We're Ready For Generic Lipitor Wednesday, 5 Mar 2008 | 2:25 PM ET

    I'm in the press room at the midtown Manhattan hotel where Pfizer is holding its analyst meeting. There's just over half a dozen reporters here and we're nearly outnumbered by PR folks. As one of them remarked, the press turnout for an event like this just isn't what it used to be...

  • Baxter, Biogen Idec & Elan Subjects of Broken Embargoes Wednesday, 5 Mar 2008 | 8:15 AM ET

    Embargoes imposed by scientific groups and medical journals will once again be put to the test over the next couple of months.

  • Pfizer Not Getting The Love Before Analyst Meeting Tuesday, 4 Mar 2008 | 3:38 PM ET

    The day before Pfizer's analyst meeting tomorrow investors are not showing much love for the beaten-down Dow component. PFE's trading in the early going today at its lowest level since December 2005.

  • Drug Money Still A "Healthy Flow" To Democrats Monday, 3 Mar 2008 | 9:29 AM ET

    On the eve of the make-or-break Texas-Ohio primaries for Sen. Hillary Clinton, she remains in first place in at least one "poll." The Center for Responsive Politics has updated its list of top pharmaceuticals/health products-industry money recipients based on the most recent campaign finance reports and the former First Lady edges out Sen. Barack Obama...

  • Lechleiter Likes Lilly--A Lot Thursday, 28 Feb 2008 | 9:50 AM ET

    When Schering-Plough Chairman and CEO Fred Hassan recently decided to buy another $2 million worth of SGP shares in the wake of the Vytorin study takedown, the company put out a press release.

  • Onyx Hires New CEO--But Here's What You Won't Find In PR Wednesday, 27 Feb 2008 | 3:28 PM ET

    Recently I've blogged and raised the question in an interview about whether Onyx Pharmaceuticals might be having a tough time finding a new leader. Well, nearly six months since longtime Chairman and CEO Hollings Renton announced his plans to retire this year, the biotech company has filled the spot.

  • Prana Biotechnology: Why I Wanted To Do Their Story Tuesday, 26 Feb 2008 | 1:13 PM ET

    I often get pitched by PR people who want me to do a story on their micro-cap biotech company. And I almost always turn them down. I know that most of the sector toils in the eight and nine digit market value space and that there's a bit of a Catch-22 at work.

  • Pfizer's CEO Kindler Being Kind To Hillary--Again Monday, 25 Feb 2008 | 1:37 PM ET

    According to The Center for Responsive Politics' web site Pfizer Chairman and CEO Jeff Kindler has opened his wallet again for Sen. Hillary Clinton. You can see his latest "give" here. Twice now within the past year Kindler has given the maximum amount ($2,300) an individual can contribute to a candidate.

  • Genentech: How It Got Its Groove Back Monday, 25 Feb 2008 | 10:42 AM ET

    I always prefer it when pharmaceutical/biotech execs and analysts can break out of their scientific/financial jargon and give good soundbites or quotes. So, among the flurry of research notes I've received over the weekend and this morning on the Genentech Avastin news the award goes to Rodman & Renshaw's Mike King who writes, "The biotech leader has its groove back."

  • Genentech's Avastin Gets "Qualified" Win From FDA Friday, 22 Feb 2008 | 4:53 PM ET

    Shortly before the closing bell trading in shares of Genentech was halted for news pending. Then, right after the bell the company issued this press release announcing the Food and Drug Administration has granted "accelerated approval" to Genentech's Avastin for use on breast cancer.

  • Waiting For FDA--In the Meantime, Your Emails Friday, 22 Feb 2008 | 12:03 PM ET

    As we sit here closely monitoring the wires and waiting for word out of Genentech and/or the FDA about a decision on Avastin for breast cancer, it seemed like as good a time as any to once again post some samples of a flood of recent emails from readers--the good, the bad and the ugly.

  • Merck, SGP's "Enhance" Study No "Late Breaker" At ACC Thursday, 21 Feb 2008 | 4:36 PM ET

    The results of the controversial study called "Enhance" of the cholesterol drug Vytorin from Merck and Schering-Plough will not be presented as a prestigious "late breaker" at the upcoming annual meeting of the American College of Cardiology.

  • Genentech's Avastin: Will FDA Give It An "Oscar"? Thursday, 21 Feb 2008 | 11:25 AM ET

    Who needs Oscar ballots? Biotech investing wonks/nerds (and I'm not suggesting I am one) might wanna start an office pool about when and what the FDA's decision will be on Genentech's drug Avastin for breast cancer.